BIO.B Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
BIO.B is not a good buy right now for a Beginner long-term investor with $50,000-$100,000 to deploy. The stock has weak technical momentum, no strong proprietary buy signal, and the latest quarter showed only slight revenue growth while profitability deteriorated sharply. The current setup supports waiting rather than buying immediately.
Technically, BIO.B is weak. MACD is negative and still below zero, moving averages are bearish with SMA_200 > SMA_20 > SMA_5, and the stock is trading below its pivot level of 268.697 near 261.27. RSI_6 at 26.739 is oversold-ish but not giving a strong reversal confirmation. The near-term pattern data also points to mild downside over the next week. This is not a strong entry setup for an impatient buyer.
Bio-Rad’s ddPCR instrument revenue grew 24% year-over-year, helped by the QX700 platform. Hedge funds are reported as strong buyers over the last quarter. The company is also shifting acquisition focus toward businesses with established revenue and margin profiles, which may improve capital deployment quality over time.
Q1 2026 results were pressured by the Middle East conflict, with management cutting full-year revenue growth guidance to -3% to +0.5%. Revenue growth was only 1.14% YoY, while net income and EPS fell sharply and gross margin declined to 52.25%. Analysts have recently lowered targets and turned more cautious, citing weak organic growth, margin pressure, and uncertainty in process chromatography and China diagnostics. No recent AI Stock Picker or SwingMax buy signal is present.
In Q1 2026, Bio-Rad reported revenue of $592.1M, up 1.14% YoY, which shows limited top-line growth. However, profitability weakened significantly: net income fell to -$527.1M and EPS to -19.55, both sharply worse year over year. Gross margin also declined to 52.25%. The latest quarter therefore shows revenue stability but poor earnings quality and margin compression, which is not attractive for a long-term beginner investor.
Analyst sentiment has turned more cautious. Wells Fargo cut its target to $290 from $320 and kept Equal Weight after a Q1 miss and guidance cuts. Citi downgraded the stock to Neutral from Buy and reduced its target to $300 from $375, citing weak recovery prospects in process chromatography and China diagnostics uncertainty. UBS is still Buy-rated but also lowered its target to $335. Overall, Wall Street is leaning cautious to neutral rather than bullish.
